AstraZeneca plc (ADR) (NYSE:AZN) came up with a new immunotherapy drug durvalumab which according to sources will move quite a long way to actually tone down the risk of stage III lung cancer worsening, or even a much worse scenario where it might end up causing death during a trial.

The product can be said to have obtained a major boost following the lately held trial and the company’s insiders have speculated that it might turn out to be the much anticipated blockbuster drug that will see the provider fetch billions of dollars.

Sources indicate that the drug which will as a matter of fact go by the brand name Imfinzi will be working on the principle of helping the immune cells of the human body face out cancer and thus offering the perfect alternative to chemotherapy and it is just amazing to witness how fast the world is moving towards coming up with top end remedies for complications that the population has been struggling with for ages.

At the moment, expert opinion has it that AstraZeneca is set to have in place a “sizable market opportunity” and this is of course in regards to facing out the advanced lung cancer and this of course refers to the potential off-label use in patients and that is during the very early stages of the complication.

The recent study has beyond any reasonable cloud of doubt indicate strong results. The medical revolution cutting across is a remarkable one considering that Imfinzi in a major way reduces the risk of death or the more advanced cancer.

One of the top researchers in his reported noted, “Overall, (the expert) viewed the top-line results as a positive surprise and expects broad uptake among eligible patients assuming the (progression-free survival benefit) seen in the full data presentation is clinically meaningful,”

It is crucial to point out one fact that may seem rather obvious, but it is a very central one! Those patients who lung cancer may prove problematic being faced out through surgery and choose to go the radiation or chemo way may as a matter of fact be subjected to pretty longer treatment durations.

Previous articleYahoo! Inc (NASDAQ:YHOO) Faces Criticism For Failure To Cooperate With An Ongoing Investigation In Regards To Information Security
Next articleCenturylink Inc (NYSE:CTL) Now Providing Gigabit Service To About 47,000 Arizona Businesses
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.